Corbus Pharmaceuticals Holdings Inc
CRBP
Company Profile
Business description
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Contact
500 River Ridge Drive
NorwoodMA02062
USAT: +1 617 963-0100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
28
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.40 | 16.50 | -0.19% |
| CAC 40 | 7,606.17 | 49.95 | -0.65% |
| DAX 40 | 23,174.85 | 142.96 | -0.61% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,808.18 | 35.29 | -0.40% |
| HKSE | 23,243.14 | 467.55 | -1.97% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,488.34 | 396.81 | -1.02% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,523.70 | 7.50 | -0.09% |
| SSE Composite Index | 3,362.11 | 26.70 | -0.79% |